Although validation of our observations should be obtained in genetically modified mice (with LDL receptor or apolipoprotein E knockout, known to develop atherosclerosis), our findings clearly highlighted hyperlipidemia repression by PACs. Here, LDLR is linked to hyperlipidemia.